Tauroursodeoxycholic acid suppresses amyloid β-induced synaptic toxicity in vitro and in APP/PS1 mice

Neurobiology of Aging

Volumn 34, Issue 2, 2013, Pages 551-561

  Ramalho, Rita M ^a   Nunes, Ana F ^a   Dias, Raquel B ^a,b   Amaral, Joana D ^a   Lo, Adrian C ^c   D'Hooge, Rudi ^c   Sebastião, Ana M ^a,b   Rodrigues, Cecilia M P ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; Amyloid ; Dendritic spines; Postsynaptic density 95 protein; Synapses; Tauroursodeoxycholic acid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PRESENILIN 1; TAUROURSODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DENDRITIC SPINE; DOWN REGULATION; EXCITATORY POSTSYNAPTIC POTENTIAL; FETUS; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; SYNAPSE; SYNAPTOSOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL DEATH; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PRESENILIN-1; RATS; RATS, WISTAR; SYNAPSES; TAUROCHENODEOXYCHOLIC ACID;

EID: 84869091863     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.04.018     Document Type: Article

References (56)

1. Ben Mosbah I., Alfany-Fernández I., Martel C., Zaouali M.A., Bintanel-Morcillo M., Rimola A., Rodés J., Brenner C., Roselló-Catafau J., Peralta C. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell. Death Dis 2010, 1:e52.
2. Brewer G.J., Torricelli J.R., Evege E.K., Price P.J. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci. Res 1993, 35:567-576.
3. Castro R.E., Ferreira D.M., Zhang X., Borralho P.M., Sarver A.L., Zeng Y., Steer C.J., Kren B.T., Rodrigues C.M. Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am. J. Physiol. Gastrointest. Liver Physiol 2010, 299:G887-G897.
4. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci 1999, 2:271-276.
5. Chen X., Winters C., Azzam R., Li X., Galbraith J.A., Leapman R.D., Reese T.S. Organization of the core structure of the postsynaptic density. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4453-4458.
6. Crosignani A., Setchell K.D., Invernizzi P., Larghi A., Rodrigues C.M., Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin. Pharmacol 1996, 30:333-358.
7. Del Mar Martínez-Senac M., Villalaín J., Gómez-Fernández J.C. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem 1999, 265:744-753.
8. Dias R.B., Ribeiro J.A., Sebastião A.M. Enhancement of AMPA currents and GluR1 membrane expression through PKA-coupled adenosine A(2A) receptors. Hippocampus 2012, 22:276-291.
9. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 1995, 16:285-298. [Discussion, 298-304].
10. Duan W.M., Rodrigues C.M., Zhao L.R., Steer C.J., Low W.C., Rodrigures C.M. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant 2002, 11:195-205.
11. Freir D.B., Holscher C., Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol 2001, 85:708-713.
12. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
13. Götz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 2004, 9:664-683.
14. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 2010, 119:523-541.
15. Gray E.G. Electron microscopy of synaptic contacts on dendrite spines of the cerebral cortex. Nature 1959, 183:1592-1593.
16. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol 2003, 60:1119-1122.
17. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol 1989, 24:173-182.
18. Kaminsky Y.G., Marlatt M.W., Smith M.A., Kosenko E.A. Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp. Neurol 2010, 221:26-37.
19. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
20. Keene C.D., Rodrigues C.M., Eich T., Chhabra M.S., Steer C.J., Low W.C. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10671-10676.
21. Keene C.D., Rodrigues C.M., Eich T., Linehan-Stieers C., Abt A., Kren B.T., Steer C.J., Low W.C. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp. Neurol 2001, 171:351-360.
22. Kubo T., Nishimura S., Kumagae Y., Kaneko I. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J. Neurosci. Res 2002, 70:474-483.
23. Lee M.C., Yasuda R., Ehlers M.D. Metaplasticity at single glutamatergic synapses. Neuron 2010, 66:859-870.
24. Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci 2011, 31:6627-6638.
25. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W., Morris J.C. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56:127-129.
26. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol 2001, 158:1345-1354.
27. McGeer E.G., McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des 1999, 5:821-836.
28. Nunes A.F., Amaral J.D., Lo A.C., Fonseca M.B., Viana R.J., Callaerts-Vegh Z., D'Hooge R., Rodrigues C.M. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol. Neurobiol 2012 Mar 23, [Epub ahead of print].
29. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci 2010, 13:812-818.
30. Pike C.J., Walencewicz-Wasserman A.J., Kosmoski J., Cribbs D.H., Glabe C.G., Cotman C.W. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem 1995, 64:253-265.
31. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jäggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Hölscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
32. Ramalho R.M., Borralho P.M., Castro R.E., Solá S., Steer C.J., Rodrigues C.M. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J. Neurochem 2006, 98:1610-1618.
33. Ramalho R.M., Ribeiro P.S., Solá S., Castro R.E., Steer C.J., Rodrigues C.M. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J. Neurochem 2004, 90:567-575.
34. Ramalho R.M., Viana R.J., Castro R.E., Steer C.J., Low W.C., Rodrigues C.M. Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol. Med 2008, 14:309-317.
35. Rodrigues C.M., Fan G., Ma X., Kren B.T., Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest 1998, 101:2790-2799.
36. Rodrigues C.M., Sola S., Nan Z., Castro R.E., Ribeiro P.S., Low W.C., Steer C.J. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6087-6092.
37. Rodrigues C.M., Spellman S.R., Solá S., Grande A.W., Linehan-Stieers C., Low W.C., Steer C.J. Neuroprotection by a bile acid in an acute stroke model in the rat. J. Cereb. Blood Flow Metab 2002, 22:463-471.
38. Rodrigues C.M., Stieers C.L., Keene C.D., Ma X., Kren B.T., Low W.C., Steer C.J. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J. Neurochem 2000, 75:2368-2379.
39. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
40. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res 2008, 192:106-113.
41. Seyhun E., Malo A., Schäfer C., Moskaluk C.A., Hoffmann R.T., Göke B., Kubisch C.H. Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, acinar cell damage, and systemic inflammation in acute pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol 2011, 301:G773-G782.
42. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci 2007, 27:2866-2875.
43. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
44. Shao C.Y., Mirra S.S., Sait H.B., Sacktor T.C., Sigurdsson E.M. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol 2011, 122:285-292.
45. Sjöström P.J., Rancz E.A., Roth A., Häusser M. Dendritic excitability and synaptic plasticity. Physiol. Rev 2008, 88:769-840.
46. Solá S., Amaral J.D., Borralho P.M., Ramalho R.M., Castro R.E., Aranha M.M., Steer C.J., Rodrigues C.M. Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis. Mol. Endocrinol 2006, 20:2292-2303.
47. Solá S., Castro R.E., Laires P.A., Steer C.J., Rodrigues C.M. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol. Med 2003, 9:226-234.
48. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem 2003, 278:11612-11622.
49. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol 1991, 30:572-580.
50. van Spronsen M., Hoogenraad C.C. Synapse pathology in psychiatric and neurologic disease. Curr. Neurol. Neurosci. Rep 2010, 10:207-214.
51. Ved R., Saha S., Westlund B., Perier C., Burnam L., Sluder A., Hoener M., Rodrigues C.M., Alfonso A., Steer C., Liu L., Przedborski S., Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem 2005, 280:42655-42668.
52. Viana R.J., Nunes A.F., Castro R.E., Ramalho R.M., Meyerson J., Fossati S., Ghiso J., Rostagno A., Rodrigues C.M. Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell. Mol. Life Sci 2009, 66:1094-1104.
53. Viana R.J., Ramalho R.M., Nunes A.F., Steer C.J., Rodrigues C.M. Modulation of amyloid-beta peptide-induced toxicity through inhibition of JNK nuclear localization and caspase-2 activation. J. Alzheimers Dis 2010, 22:557-568.
54. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
55. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
56. Yuste R., Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu. Rev. Neurosci 2001, 24:1071-1089.